Cezary Ciszewski1, Valentina Discepolo1, Alain Pacis2, Nick Doerr3, Olivier Tastet2, Toufic Mayassi4, Mariantonia Maglio5, Asjad Basheer3, Laith Q Al-Mawsawi3, Peter H R Green6, Renata Auricchio5, Riccardo Troncone5, Thomas A Waldmann7, Nazli Azimi3, Yutaka Tagaya8, Luis B Barreiro9, Bana Jabri10. 1. Department of Medicine, University of Chicago, Chicago, Illinois. 2. Department of Genetics, CHU Sainte-Justine Research Center, Montreal, Quebec, Canada. 3. Bioniz Therapeutics, Inc., Irvine, California. 4. Department of Medicine, University of Chicago, Chicago, Illinois; Committee on Immunology, University of Chicago, Chicago, Illinois. 5. Department of Translational Medical Science and European Laboratory for the Investigation of Food Induced Diseases (ELFID), Università degli Studi di Napoli Federico II, Napoli, Italy. 6. Celiac Disease Center, Columbia University, New York, New York. 7. Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, Maryland. 8. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland. 9. Department of Medicine, University of Chicago, Chicago, Illinois; Committee on Genetics, Genomics and Systems Biology, University of Chicago, Chicago, Illinois. 10. Department of Medicine, University of Chicago, Chicago, Illinois; Committee on Immunology, University of Chicago, Chicago, Illinois; Department of Pathology and Pediatrics, University of Chicago, Chicago, Illinois. Electronic address: bjabri@bsd.uchicago.edu.
Abstract
BACKGROUND & AIMS: Gamma chain (γc) cytokines (interleukin [IL]2, IL4, IL7, IL9, IL15, and IL21) signal via a common γc receptor. IL2 regulates the immune response, whereas IL21 and IL15 contribute to development of autoimmune disorders, including celiac disease. We investigated whether BNZ-2, a peptide designed to inhibit IL15 and IL21, blocks these cytokines selectively and its effects on intraepithelial cytotoxic T cells. METHODS: We obtained duodenal biopsies from 9 patients with potential celiac disease (positive results from tests for anti-TG2 but no villous atrophy), 30 patients with untreated celiac disease (with villous atrophy), and 5 patients with treated celiac disease (on a gluten-free diet), as well as 43 individuals without celiac disease (controls). We stimulated primary intestinal intraepithelial CD8+ T-cell lines, or CD8+ T cells directly isolated from intestinal biopsies, with γc cytokines in presence or absence of BNZ-2. Cells were analyzed by immunoblots, flow cytometry, or RNA-sequencing analysis for phosphorylation of signaling molecules, gene expression profiles, proliferation, and levels of granzyme B. RESULTS: Duodenal tissues from patients with untreated celiac disease had increased levels of messenger RNAs encoding IL15 receptor subunit alpha (IL15RA) and IL21 compared with tissues from patients with potential celiac disease and controls. Activation of intraepithelial cytotoxic T cells with IL15 or IL21 induced separate signaling pathways; incubation of the cells with IL15 and IL21 cooperatively increased their transcriptional activity, proliferation, and cytolytic properties. BNZ-2 specifically inhibited the effects of IL15 and IL21, but not of other γc cytokines. CONCLUSIONS: We found increased expression of IL15RA and IL21 in duodenal tissues from patients with untreated celiac disease compared with controls. IL15 and IL21 cooperatively activated intestinal intraepithelial cytotoxic T cells. In particular, they increased their transcriptional activity, proliferation, and cytolytic activity. The peptide BNZ-2 blocked these effects, but not those of other γc cytokines, including IL2. BNZ-2 might be used to prevent cytotoxic T-cell-mediated tissue damage in complex immune disorders exhibiting upregulation of IL15 and IL21.
BACKGROUND & AIMS: Gamma chain (γc) cytokines (interleukin [IL]2, IL4, IL7, IL9, IL15, and IL21) signal via a common γc receptor. IL2 regulates the immune response, whereas IL21 and IL15 contribute to development of autoimmune disorders, including celiac disease. We investigated whether BNZ-2, a peptide designed to inhibit IL15 and IL21, blocks these cytokines selectively and its effects on intraepithelial cytotoxic T cells. METHODS: We obtained duodenal biopsies from 9 patients with potential celiac disease (positive results from tests for anti-TG2 but no villous atrophy), 30 patients with untreated celiac disease (with villous atrophy), and 5 patients with treated celiac disease (on a gluten-free diet), as well as 43 individuals without celiac disease (controls). We stimulated primary intestinal intraepithelial CD8+ T-cell lines, or CD8+ T cells directly isolated from intestinal biopsies, with γc cytokines in presence or absence of BNZ-2. Cells were analyzed by immunoblots, flow cytometry, or RNA-sequencing analysis for phosphorylation of signaling molecules, gene expression profiles, proliferation, and levels of granzyme B. RESULTS: Duodenal tissues from patients with untreated celiac disease had increased levels of messenger RNAs encoding IL15 receptor subunit alpha (IL15RA) and IL21 compared with tissues from patients with potential celiac disease and controls. Activation of intraepithelial cytotoxic T cells with IL15 or IL21 induced separate signaling pathways; incubation of the cells with IL15 and IL21 cooperatively increased their transcriptional activity, proliferation, and cytolytic properties. BNZ-2 specifically inhibited the effects of IL15 and IL21, but not of other γc cytokines. CONCLUSIONS: We found increased expression of IL15RA and IL21 in duodenal tissues from patients with untreated celiac disease compared with controls. IL15 and IL21 cooperatively activated intestinal intraepithelial cytotoxic T cells. In particular, they increased their transcriptional activity, proliferation, and cytolytic activity. The peptide BNZ-2 blocked these effects, but not those of other γc cytokines, including IL2. BNZ-2 might be used to prevent cytotoxic T-cell-mediated tissue damage in complex immune disorders exhibiting upregulation of IL15 and IL21.
Authors: E M Nilsen; F L Jahnsen; K E Lundin; F E Johansen; O Fausa; L M Sollid; J Jahnsen; H Scott; P Brandtzaeg Journal: Gastroenterology Date: 1998-09 Impact factor: 22.682
Authors: Michal Marzec; Krzysztof Halasa; Monika Kasprzycka; Maria Wysocka; Xiaobin Liu; John W Tobias; Donald Baldwin; Qian Zhang; Niels Odum; Alain H Rook; Mariusz A Wasik Journal: Cancer Res Date: 2008-02-15 Impact factor: 12.701
Authors: Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard Journal: J Exp Med Date: 2005-01-03 Impact factor: 14.307
Authors: Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors Journal: Nat Rev Gastroenterol Hepatol Date: 2020-11-20 Impact factor: 46.802
Authors: Olivier B Bakker; Aarón D Ramírez-Sánchez; Zuzanna A Borek; Niek de Klein; Yang Li; Rutger Modderman; Yvonne Kooy-Winkelaar; Marie K Johannesen; Filomena Matarese; Joost H A Martens; Vinod Kumar; Jeroen van Bergen; Shuo-Wang Qiao; Knut E A Lundin; Ludvig M Sollid; Frits Koning; Cisca Wijmenga; Sebo Withoff; Iris H Jonkers Journal: Sci Rep Date: 2021-04-29 Impact factor: 4.379
Authors: Olivia J James; Maud Vandereyken; Julia M Marchingo; Francois Singh; Susan E Bray; Jamie Wilson; Andrew G Love; Mahima Swamy Journal: Nat Commun Date: 2021-07-13 Impact factor: 14.919